Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Vulvovaginal candidiasis
- Focus Registrational; Therapeutic Use
- Acronyms VANISH 303
- Sponsors SCYNEXIS
- 01 Feb 2023 Results of pooled analysis assessing the effectiveness of ibrexafungerp in various patient subgroups that may impact outcomes in VANISH 303 (NCT03734991) and VANISH 306 (NCT03987620) were published in the Journal of Women's Health.
- 03 Nov 2022 According to a SCYNEXIS media release, pooled results from VANISH-303 and VANISH-306 studies were peer-reviewed published in the Journal of Women's Health.
- 03 Nov 2022 Pooled results from VANISH-303 and VANISH-306 studies presented in a SCYNEXIS media release.